Background: Proprotein convertase subtilisin-kexin type 9 inhibitors (PCSK9-I) reduce low-density lipoprotein (LDL) cholesterol in human studies. Previous studies suggest that PCSK9-I may also affect very-low-density lipoproteins (VLDL). We therefore studied VLDL size and composition in a "real-world" study population with the use of β-quantification.
Subjects And Methods: 350 patients (62 ± 11 years old, 58% men, 22% with diabetes mellitus) with different concomitant lipid lowering therapies, and in whom PCSK9-I treatment was indicated, received either evolocumab (140 mg) or alirocumab (75 or 150 mg). The major lipoprotein fractions were separated by β-quantification and lipid and apolipoprotein compositions were determined before and 4 weeks after initiation of PCSK9-I treatment.
Results: After 4 weeks of PCSK9-I treatment, the ratio of triglycerides to apolipoprotein B in VLDL particles (VLDL-TG/apoB ratio) increased by 40% (p < .0001). VLDL-associated apolipoproteins E, CII, and CIII were reduced by 29.4%, 16.4%, and 12.4%, respectively (all p < .0001).
Conclusion: PCSK9-I treatment increased VLDL size (estimated by an increased VLDL-TG/apoB ratio) and reduced VLDL-associated apolipoproteins in a heterogeneous "real-world" study-population, reflecting a higher clearance of small atherogenic VLDL remnant particles by PCSK9-I. This may potentially lower cardiovascular risk in clinical routine patients beyond low-density cholesterol (LDL-C) reduction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vph.2019.03.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipoprotein (a): Underrecognized Risk with a Promising Future.
Rev Cardiovasc Med
November 2024
Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Lipoprotein a (Lp(a)) is a lipid biomarker that binds cholesterol and bears independent cardiovascular risk. Strategies to lower the level of Lp(a) and mitigate such risk are important both for primary and secondary prevention. Currently there are no approved therapies targeting Lp(a) directly.
View Article and Find Full Text PDFEffectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records.
PLoS One
August 2024
Cardiovascular Center, Territorial Specialistic Department, University Hospital and Health Services of Trieste, Trieste, Italy.
Article Synopsis
- LDL cholesterol is a major focus for preventing cardiovascular events, and Proprotein Convertase Subtilisin-Kexin type 9 inhibitors (PCSK9-i) have become an important treatment to lower LDL levels.
- A recent study aimed to understand how many people qualify for PCSK9-i treatment and how effective it is by analyzing electronic health records from 2017 to 2020.
- Results showed that only 8% of eligible individuals received PCSK9-i, but those treated experienced a significant reduction in the risk of death and hospitalizations compared to those who didn't receive the treatment.
Lp(a) in the Pathogenesis of Aortic Stenosis and Approach to Therapy with Antisense Oligonucleotides or Short Interfering RNA.
Int J Mol Sci
October 2023
Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy.
Article Synopsis
- There is currently no medicine that can slow down a serious heart problem called aortic stenosis, which often happens to older people.
- Doctors can now better diagnose it using special imaging technology, and new tools like artificial intelligence may help catch it even earlier.
- Researchers are testing new drugs that could lower certain fat levels in the blood to see if they can help prevent or slow down aortic stenosis, and some of these drugs have shown promise in early studies.
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Int J Mol Sci
July 2023
Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80134 Naples, Italy.
This review aims to examine the complex interaction between dyslipidemia, platelet function, and related drug treatments. In particular, the manuscript provides an overview of the effects of major hypolipidemic drugs on platelet function. Indeed, growing evidence supports the view that statins, ezetimibe, PCSK9 inhibitors, inclisiran, and icosapent ethyl also act as antithrombotics.
View Article and Find Full Text PDFHow Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment.
Genes (Basel)
March 2023
Department of Pediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, The Netherlands.
Familial hypercholesterolemia (FH) is a hereditary disorder that causes severely elevated low-density lipoprotein (LDL-C) levels, which leads to an increased risk for premature cardiovascular disease. A variety of genetic variants can cause FH, namely variants in the genes for the LDL receptor (), apolipoprotein B (), proprotein convertase subtilisin/kexin type 9 (), and/or LDL-receptor adaptor protein 1 (). Variants can exist in a heterozygous form (HeFH) or the more severe homozygous form (HoFH).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!